Aroxybutynin and Atomoxetine (AD109) Reduces Obstructive Sleep Apnea Budren in Phase 3 SynAIRgy

Combination aroxybutynin and atomoxetine (AD109) provided statistically significant improvement to apnea-hypopnea index (AHI) scores in patients with obstructive sleep apnea (OSA) across multiple weight classes, according to findings from the…